In 2013, when I had the diagnosis of neuro endocrine tumor (NET) in my pancreas, Keisha had to make dozens of emotional and time-consuming phone calls and emails. I had been functionally depressed 4 years prior to the diagnosis so I was completely “out of it”. My psychiatrist introduced me to CaringBridge and here is my website. Here is the powerful connection point, CaringBridge makes it possible for you to easily offer support and encouragement.
In 2002, CaringBridge became a 501(c)(3) nonprofit organization, providing support when it’s needed most. In times of need, the greatest source of hope and healing is the love of family and friends. Most of you have asked how you can help, I have links to organizations that provide care for me and are working hard to research cures for this chronic disease. PLEASE DONATE!
TIMELINE * February 2013 - Diagnosed Pancreatic Neuro Endocrine Tumor (PNET) * July 2013 - Partial pancreatectomy * March 2014 - Thyroid nodule * March 2014 - Thyroidectomy * October 2014 - Thyroidectomy * June 2017 - PNET Recurrence * May 2018 - Peptide Receptor Radionuclide Therapy (PRRT)
MY STORY Diagnosed with Pancreatic Neuro Endocrine Tumor (PNET) in February 2013, I was in remission until June 2017. I am a husband, father, brother, uncle and a Human Evolution Intersectionalist. When not in treatment, I spend my days in a variety of roles, however I am most proud of the time I spend at my daughter’s school as playground supervisor.
Also, living with a bipolar disorder diagnosis, activities of daily living (ADL) have to be particularly stress free. I manage stress by walking (treadmill during inclement weather) and pumping iron at the YMCA.
With the recurrence of my NET, my oncologist and surgeon thought surgery to remove the tumor will be an option worth consideration. After many sleepless nights and consultation with dear family, friends and my medical team, it felt the timing was just right to use the option provided by the just approved FDA drug Lutetium 177 DOTA-TATE (Lu 177), used for Peptide Receptor Radionuclide Therapy (PRRT). Lu 177 was approved in January 2018 for the treatment of somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NET’s) including foregut, midgut and hindgut tumors in adults.
MY GOAL IN SHARING MY STORY I think of what we can do together! In my gallery, I share pictures of myself and some relatives who have died or are in remission from cancer. It is amazing how fast research is producing drugs/treatments to slow the growth of cancer cells and in some cases cure .
“F U N D research 4 the patient of T O M O R R O W” is my appeal to you.
On my journey in 2013, PRRT was not available in the US. The gold standard was to remove the tumor and live life with resulting variables that impacted ADL.
How You Can Help: I encourage you to peruse my journal and donate directly to courses you believe in. Thank you for reading and sharing my story. Peace be yours!